News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Week In Review: The Biotech Bounce


10/19/2005 5:13:15 PM

April 10, 2005 -- For most of the past week, the bounce has been the story. After hitting a 52-week low on Monday, the Centient Biotech 200 put in four straight winning sessions, rising a net 107 points over the five days to 3045.68, a 3.5% gain. The NYSE Composite was up .63%, and Nasdaq climbed .73%. For the year, the CBT 200 is down 11.2%. Currently, the index stands 15.5% below its highs of almost a year ago, and it closed Friday 4.3% higher than the closing low set this week Monday. EntreMed was the big winner of the week, announcing good clinical news, and CancerVax was the big loser, the beneficiary of bad clinical results. Pfizer dominated the news last week. Given its $28 billion of repatriated profits, it will continue to make news. Plus the company has the financial wherewithal to... Well, we speculate a little. More details...


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES